Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co's depression drug fails late-stage trial - Reuters


Thursday, 5 Dec 2013 08:17am EST 

Eli Lilly And Co:Says its experimental drug to treat depression failed to meet it primary goal in three late-stage trials and the drugmaker will not seek approval of the medicine for that condition - Reuters.Says drug edivoxetine, a member of a family of medicines called norepinephrine reuptake inhibitors, was tested in combination with a member of a widely used class of depression treatments called selective serotonin reuptake inhibitors (SSRIs) in each of the three trials.Says after eight weeks of treatment, the combination of drugs that included edivoxetine did not prove superior to the SSRIs alone, thereby failing the main goal of the study. 

Company Quote

65.08
0.23 +0.35%
1 Oct 2014